Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All PPI studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPPIsPPIs (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Interest of Proton Pump Inhibitors in Reducing the Occurrence of COVID-19: A Case-Control Study

Blanc et al., Preprints, doi:10.20944/preprints202005.0016.v1
May 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Case 56% Improvement Relative Risk PPIs for COVID-19  Blanc et al.  Prophylaxis Do PPIs reduce COVID-19 infections? Retrospective 179 patients in France (March - April 2020) Fewer cases with PPIs (p=0.0053) c19early.org Blanc et al., Preprints, May 2020 FavorsPPI Favorscontrol 0 0.5 1 1.5 2+
PPIs for COVID-19
1st treatment shown to increase risk in September 2020
 
*, now with p = 0.00000031 from 37 studies.
* From meta analysis with ≥3 studies.
4,700+ studies for 94 treatments. c19early.org
Retrospective 179 elderly patients in France, showing higher risk of COVID-19 cases with acetaminophen use, without statistical significance.
Study covers PPIs and acetaminophen.
risk of case, 56.2% lower, OR 0.44, p = 0.005, treatment 63, control 116, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Blanc et al., 2 May 2020, retrospective, France, preprint, mean age 84.1, 22 authors, study period 2 March, 2020 - 8 April, 2020.
This PaperPPIsAll
{ 'indexed': {'date-parts': [[2022, 7, 14]], 'date-time': '2022-07-14T07:32:23Z', 'timestamp': 1657783943788}, 'posted': {'date-parts': [[2020, 5, 2]]}, 'group-title': 'MEDICINE &amp; PHARMACOLOGY', 'reference-count': 0, 'publisher': 'MDPI AG', 'license': [ { 'start': { 'date-parts': [[2020, 5, 2]], 'date-time': '2020-05-02T00:00:00Z', 'timestamp': 1588377600000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 4, 28]]}, 'abstract': '<jats:p>Background: COVID-19 is a disease of the elderly as 95% of deaths related to COVID-19 ' 'occur in people over 60 years of age. Despite the urgent need for a preventive treatment ' 'there are currently no serious leads, other than the vaccination. Objective: To find a ' 'preventive treatment of COVID-19 in elderly patients. Design: Retrospective case-control ' 'study. Setting: Robertsau Geriatric Hospital of the University Hospitals of Strasbourg, ' 'France. Patients: 179 elderly patients who had been in contact with the SARS-CoV-2, of whom ' '89 had tested RT-PCR-positive (COVID-pos) for the virus and 90 had tested RT-PCR-negative ' '(COVID-neg). Measurements: Treatments within 15 days prior to RT-PCR (including ' 'antihypertensive drugs, antipsychotics, antibiotics, nonsteroidal anti-inflammatory drugs, ' 'proton pump inhibitors (PPIs), paracetamol, anticoagulant, oral antidiabetics (OADs), ' 'corticosteroids, immunosuppressants), comorbidities, symptoms, laboratory values, and ' 'clinical outcome were all collected using the electronic patient record. Results: COVID-pos ' 'patients more frequently had a history of diabetes (P=.016) and alcoholism (P=.023), a lower ' 'leukocyte count (P=.014) and a higher mortality rate&amp;ndash; 29.2% versus 14.4% ' '&amp;ndash; (P=.014) when compared to COVID-neg patients. Patients on PPIs were 2.3 times ' 'less likely (odds ratio [OR] = 0.4381, 95% confidence interval [CI] [0.2331, 0.8175], ' 'P=.0053) to develop COVID-19 infection, compared to those not on PPIs. No other treatment ' 'decreased or increased this risk. COVID-19 patients on antipsychotics (P=.0013) and OADs ' '(P=.0166) were less likely to die. Limitations: retrospective study. Conclusion: PPIs ' 'treatment lowered the risk of development of COVID-19 infection, and antipsychotics and OADs ' 'decreased the risk of mortality in geriatric patients. If further studies confirm this ' 'finding, PPIs could be used preventatively in the elderly in this pandemic context. Moreover, ' 'OADS and antipsychotics should be tested in clinical trials.</jats:p>', 'DOI': '10.20944/preprints202005.0016.v1', 'type': 'posted-content', 'created': {'date-parts': [[2020, 5, 4]], 'date-time': '2020-05-04T16:19:38Z', 'timestamp': 1588609178000}, 'source': 'Crossref', 'is-referenced-by-count': 5, 'title': 'Interest of Proton Pump Inhibitors in Reducing the Occurrence of COVID-19: A Case-Control Study', 'prefix': '10.20944', 'author': [ {'given': 'Frederic', 'family': 'Blanc', 'sequence': 'first', 'affiliation': []}, {'given': 'Cedric', 'family': 'Waechter', 'sequence': 'additional', 'affiliation': []}, {'given': 'Thomas', 'family': 'Vogel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Benoît', 'family': 'Schorr', 'sequence': 'additional', 'affiliation': []}, {'given': 'Catherine', 'family': 'Demuynck', 'sequence': 'additional', 'affiliation': []}, {'given': 'Catherine', 'family': 'Martin-Hunyadi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maxence', 'family': 'Meyer', 'sequence': 'additional', 'affiliation': []}, {'given': 'Denata', 'family': 'Mutelica', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nadjiba', 'family': 'Bougaa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Samira', 'family': 'Fafi-Kremer', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lidia', 'family': 'Calabrese', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elise', 'family': 'Schmitt', 'sequence': 'additional', 'affiliation': []}, {'given': 'Delphine', 'family': 'Imperiale', 'sequence': 'additional', 'affiliation': []}, {'given': 'Catherine', 'family': 'Jehl', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexandre', 'family': 'Boussuge', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carmen', 'family': 'Suna', 'sequence': 'additional', 'affiliation': []}, {'given': 'François', 'family': 'Weill', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexia', 'family': 'Matzinger', 'sequence': 'additional', 'affiliation': []}, {'given': 'Candice', 'family': 'Muller', 'sequence': 'additional', 'affiliation': []}, {'given': 'Patrick', 'family': 'Karcher', 'sequence': 'additional', 'affiliation': []}, {'given': 'Georges', 'family': 'Kaltenbach', 'sequence': 'additional', 'affiliation': []}, {'given': 'Erik', 'family': 'Sauleau', 'sequence': 'additional', 'affiliation': []}], 'member': '1968', 'container-title': [], 'original-title': [], 'deposited': { 'date-parts': [[2020, 5, 4]], 'date-time': '2020-05-04T16:20:08Z', 'timestamp': 1588609208000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.preprints.org/manuscript/202005.0016/v1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 5, 2]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.20944/preprints202005.0016.v1', 'relation': {}, 'published': {'date-parts': [[2020, 5, 2]]}, 'subtype': 'preprint'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit